Castle Biosciences, Inc.
Moat Score — Castle Biosciences, Inc.
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Proprietary multi-analyte algorithms backed by extensive peer-reviewed clinical validation data across multiple test lines create a genuine, hard-to-replicate evidentiary moat. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a specialized laboratory-developed test provider, Castle has no meaningful structural cost advantage versus larger diagnostics labs like Labcorp. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Reimbursement rates are largely payor-determined, and the DecisionDx-SCC Medicare coverage loss shows pricing/coverage can be revoked, though established tests retain negotiated reimbursement levels. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | More test usage generates more outcomes data that can strengthen future clinical validation and algorithm refinement, a mild data network effect rather than a strong one. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once physicians integrate a test into their clinical decision pathway and payors establish coverage policies, switching to alternatives involves meaningful clinical and administrative friction. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Castle holds a leading position in several niche molecular diagnostic categories (e.g., melanoma GEP testing) too small to attract multiple large-scale competitors, though this could change as it enters the much larger AdvanceAD-Tx market. |